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Background. The frequent lack of a microbiological diagnosis in community-acquired pneumonia (CAP) impairs pathogen-
directed antimicrobial therapy. This study assessed the use of comprehensive multibacterial, multiviral molecular testing,
including quantification, in adults hospitalized with CAP.
Methods. Clinical and laboratory data were collected for 323 adults with radiologically-confirmed CAP admitted to 2 UK
tertiary care hospitals. Sputum (96%) or endotracheal aspirate (4%) specimens were cultured as per routine practice and also tested
with fast multiplex real-time polymerase-chain reaction (PCR) assays for 26 respiratory bacteria and viruses. Bacterial loads were also
calculated for 8 bacterial pathogens. Appropriate pathogen-directed therapy was retrospectively assessed using national guidelines
adapted for local antimicrobial susceptibility patterns.
Results. Comprehensive molecular testing of single lower respiratory tract (LRT) specimens achieved pathogen detection in 87%
of CAP patients compared with 39% with culture-based methods. Haemophilus influenzae and Streptococcus pneumoniae were the
main agents detected, along with a wide variety of typical and atypical pathogens. Viruses were present in 30% of cases; 82% of these
were codetections with bacteria. Most (85%) patients had received antimicrobials in the 72 hours before admission. Of these, 78%
had a bacterial pathogen detected by PCR but only 32% were culture-positive (P < .0001). Molecular testing had the potential to
enable de-escalation in number and/or spectrum of antimicrobials in 77% of patients.
Conclusions. Comprehensive molecular testing significantly improves pathogen detection in CAP, particularly in antimicrobial-
exposed patients, and requires only a single LRT specimen. It also has the potential to enable early de-escalation from broad-
spectrum empirical antimicrobials to pathogen-directed therapy.
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Community-acquired pneumonia (CAP) is a common infec-
tious disease with an estimated incidence of 2–11 cases per
1000 adults in the developed world and a mortality rate of
2%–14% [1–5]. Due to the range of pathogens responsible for
CAP, in moderate or severe infection, broad-spectrum antimi-
crobial cover should be initiated before de-escalating to narrow-
spectrum pathogen-directed agents once a microbiological
diagnosis has been made [1, 5]. Unfortunately, de-escalation is
uncommon in practice because current diagnostic methods may
identify a pathogen in only 30%–40% of patients with CAP [4, 6,
7]. Recent studies have highlighted the need for more timely
and sensitive microbiological diagnostic methods in CAP,
particularly for bacteria and in the common scenario of antibi-
otic administration prior to sampling [4, 8, 9].
The development of multiplex real-time polymerase-chain
reaction (PCR) assays currently enables a respiratory specimen
to be rapidly screened for a wide range of viral and atypical bac-
terial pathogens in a small number of reactions [10–15]. How-
ever, a similar approach has not yet been adopted for typical
bacterial pathogens. It is difficult to interpret PCR results for
typical respiratory bacteria in nonsterile samples such as spu-
tum due to the potential for contamination with the same
organisms from oropharyngeal flora. However, accurate molec-
ular quantification of bacterial loads may aid in distinguishing
infection from contamination in a way that is analogous to the
use of quantitative cultures.
Quantitative molecular assays for typical respiratory bacteria
have been used previously in patients with pneumonia, but these
assays lack a number of key targets, use targets that have been
shown to lack specificity, or may be only semiquantitative [16–
32]. However, our group recently developed a suitable assay that
is capable of quantifying bacterial loads of 8 typical bacterial path-
ogens from lower respiratory tract (LRT) specimens [33]. This
assay was extensively validated on clinical isolates, reference
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strains, and clinical specimens such as sputa and bronchoalveolar
lavage fluids, and all bacterial targets could be reliably quantified,
even when present in mixtures of different concentrations [33].
Our aim in the study was to assess the utility of a comprehen-
sive molecular diagnostic approach encompassing 26 respiratory
bacterial and viral pathogens and including bacterial quantifica-
tion in patients with CAP.
METHODS
Patients and Study Criteria
Patients presented to 2 tertiary care hospitals in Edinburgh,
United Kingdom, over an 18-month period between September
2012 and February 2014. Consecutive cases with clinical and ra-
diological evidence of CAP were identified through daily retro-
spective electronic review of all respiratory samples received by
our microbiology laboratory. Inclusion criteria for the study in-
cluded the following: adult (aged ≥18 years); LRT specimen ob-
tained within 48 hours of admission to the hospital; new
radiographic infiltrate as determined by radiologist or consul-
tant respiratory physician; and 3 of more of the following
signs or symptoms: new or worsening cough, new or worsening
expectoration of sputum, hemoptysis, new or worsening dysp-
nea, pleuritic chest pain, fever, headache, or abnormalities on
chest auscultation or percussion. Exclusion criteria included
the following: bronchiectasis, cystic fibrosis, or healthcare-
associated pneumonia (hospitalized in an acute care hospital
for 2 or more days within 90 days of the infection or resided
in a nursing home or long-term care facility) [34]. Radiology
reports were reviewed for all patients, and only patients with
radiological changes consistent with pneumonia were included.
Where there was any uncertainty, the images were reviewed by
an experienced respiratory physician (A. T. H.). Clinical data
including comorbidities, outcomes, and antibiotic prescriptions
were collected retrospectively from patient hospital records
using a standard pro forma as part of a clinical audit of pneu-
monia management (approved by the Quality Improvement
Team, Royal Infirmary of Edinburgh). Drug administration
prior to hospitalization, including antibiotic prescription, was
obtained from the electronic primary care prescription records
on admission and later verified by a pharmacist.
Microbiological Culture and Molecular Testing
LRT specimens were cultured according to national standard
protocols to detect common respiratory bacteria [35]. Isolates
were identified using standard biochemical methods and/or
matrix-assisted laser desorption/ionization time-of-flight
(Bruker, Coventry, United Kingdom). Specimens with any
named bacterial species identified by culture were considered
to be culture positive. Following routine culture, LRT specimens
were centrifuged, and mucopurulent material was stored at
−80°C for up to 15 months. As part of the study protocol, spec-
imens and associated clinical data were collected and
anonymized before molecular testing in accordance with local
ethical approval (South East Scotland Scottish Academic Health
Sciences Collaboration Human Annotated BioResource refer-
ence no. 10/S1402/33). Thawed specimens were homogenized
by vortexing with sterile glass beads, and a 200-μL aliquot
was treated with lysozyme at 37°C followed by proteinase K at
56°C for 1 hour each. Total nucleic acid was then extracted
using the automated nucliSENS easyMAG (BioMérieux,
Basingstoke, United Kingdom) instrument with an off-board
lysis protocol, including the addition of phocine herpes virus
as an internal extraction control. Extracts were stored at 4°C
for up to 5 days or longer at −80°C. Fast multiplex real-time
PCR was performed using a combination of multiplex assays
developed or adapted in-house for the following 26 pathogens:
Streptococcus pneumoniae; Haemophilus influenzae; Moraxella
catarrhalis; Staphylococcus aureus; Escherichia coli; Klebsiella
pneumoniae; Pseudomonas aeruginosa; Acinetobacter bauman-
nii; Mycoplasma pneumoniae; Chlamydophila pneumoniae;
Chlamydophila psittaci; Legionella pneumophila; Legionella
spp.; influenza A; influenza B; respiratory syncytial virus; para-
influenza virus types 1–3; adenovirus; human coronaviruses
229E, HKU1, NL63, and OC43; human metapneumovirus;
and rhinovirus [10–15, 33]. As previously described [33], bacte-
rial loads for S. pneumoniae, H. influenzae, M. catarrhalis,
S. aureus, E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii
were expressed as colony forming units (CFUs) per milliliter of
purulent material and calculated from standard curves generated
by target gene plasmid dilution series on each PCR run. Quality
control reactions (quantitative real-time PCR for GAPDH human
gene and qualitative real-time PCR for gB phocine herpes virus
internal control [IC]) were carried out on all specimens [33].
Quantitative GAPDH PCR was used as an indication of the cell
content of each specimen because the GAPDH gene is present in
human DNA. Negative (no template) controls were included on
every extraction and PCR run to check purity of reagents. Runs
were accepted if the negative controls were negative and the stan-
dard curves were linear; runs that failed quality control were re-
peated. Qualitative results were accepted if the internal control
was positive or if at least 1 other target was positive. Quantitative
results were accepted if the internal control quantification cycle
(Cq) value fell within the range ±1 log Cq difference to negative
extraction controls. Outside of this range, quantitative results
were not accepted due to the potential for partial PCR inhibition
leading to inaccuracy of measurement.
Estimating Impact on Antimicrobial Prescribing
The prescribed empirical therapy for each patient was compared
with what antimicrobial(s) would have been appropriate for
pathogen-directed therapy, based on the molecular identification
result. Appropriate pathogen-directed therapy was determined
using UK national guidelines adapted for local antimicrobial sus-
ceptibility patterns (Supplementary Table 1) [1].










Categorical variables were compared using Fisher exact test or χ2
test. Continuous data were assessed using the Shapiro–Wilk W
test for nonnormality and analyzed using the Mann–Whitney U
test or t test. The McNemar test was used to compare paired
proportions. The Bonferroni method was used to correct for
multiple comparisons during significance testing. To control
for potential confounding factors that affect associations with
the outcome of infection, we used logistic regression analysis.
For the analysis of the outcome of infection, a combined out-
come measure of 30-day mortality and/or intensive care unit
(ICU) admission was used because of the infrequent occurrence
of either event in our cohort. Data were analyzed using StatsDir-
ect software, version 2.8 0 (Altrincham, United Kingdom).
RESULTS
Patient Characteristics
A total of 323 hospitalized adult patients with CAP were includ-
ed in the study cohort; 55% were male and the median age was
67 years (Table 1). Critical care admission (ICU or high-
dependency unit) was required for 18.6% of patients, with
12.4% admitted specifically to the ICU. Total 30-day mortality
was 6.2%.
Pathogen Detection by Molecular and Conventional Testing of LRT
Specimens
A total of 323 LRT specimens were received from 323 patients;
310 (96.0%) were sputa and 13 (4.0%) were endotracheal aspi-
rates. Culture-based microbiological testing identified a bacterial
pathogen in 127 (39.3%) patients. All specimens were positive by
PCR for the human gene target GAPDH, with an average load of
1.24 × 105 ± 1.18 × 105 gene copies per reaction; all specimens
met quality control criteria for qualitative molecular testing.
Bacteria were detected by molecular testing in specimens
from 262 (81.1%) patients (Table 2). When a cutoff of ≥105
CFU/mL was applied for assays where bacterial load was quan-
tified, bacteria were detected in specimens from 231 (71.5%) pa-
tients. Including respiratory virus results, overall pathogen
detection by molecular testing rose to 86.7% (n = 280; Table 2).
H. influenzae and S. pneumoniaewere the most frequently iden-
tified bacteria in patients with CAP, detected in 130 (40.2%) and
115 (35.6%) patients, respectively. Detection of more than 1 bac-
terial species occurred in 102 (31.6%) patients. H. influenzae or S.
pneumoniaewere present in 94 (92.2%) codetections. Viruses were
detected in 98 (30.3%) patients (Table 2); rhinovirus was most
commonly detected (12.7%, n = 41) followed by influenza A/B
(7.1%, n = 23). However, viruses alone were found in only 18
(5.6%) of our patients, with 80 (81.6%) viruses codetected with
bacteria (Table 2). The most common combination was rhinovirus
with H. influenzae and/or S. pneumoniae in 30 (37.5%) cases.
PCR detected significantly more H. influenzae, S. pneumo-
niae, M. catarrhalis, S. aureus, E. coli, and K. pneumoniae
than standard culture-based methods (Supplementary Table 2).
Of 127 culture-positive specimens, 125 (98.4%) were also PCR
positive for the same species of bacteria; the 2 discrepant spec-
imens were H. influenzae culture positive but culture negative
by PCR. Significantly, PCR was able to detect bacteria in 143
culture-negative specimens. Specimens from 27 (8.4%) patients
grew bacteria that were not included in our PCR assays (Supple-
mentary Table 3).
Bacterial Load
Bacterial load quantifications from 29 (9.1%) specimens were
excluded from analysis due to the detection of partial inhibition
Table 1. Characteristics of Included Patients With Community-Acquired
Pneumonia (n = 323)
Demographics N (%)
Male (%) 177 (54.8)
Age, median (interquartile range) years 67, 51–78
Age ≥65 y (%) 182 (56.3)
Age ≥75 y (%) 111 (34.4)
Comorbidity
Chronic obstructive pulmonary disease 128 (39.6)
Ischemic heart disease or heart failure 91 (28.2)
Immunosuppressiona 43 (13.3)
Diabetes mellitus 36 (11.1)
Neoplastic disease 31 (9.6)
Cerebrovascular disease 22 (6.8)
Chronic kidney disease 22 (6.8)















Admission C-reactive protein, mg/L (interquartile range)d 149.9 (43–246.5)
Antimicrobial administration




Intensive care unit admission 40 (12.4)
Intubation and ventilation 24 (7.4)
Vasopressor requirement 19 (5.9)
Total 30-day mortality 20 (6.2)
Abbreviation: CURB-65, confusion of new onset, blood urea nitrogen >7 mmol/l , respiratory
rate ≥30 breaths per minute, blood pressure <90mmHg systolic or ≤60 mmHg diastolic, age
≥65 years.
a Immunosuppressive drugs, human immunodeficiency virus infection, inherited
immunodeficiency syndromes, hematological malignancy.
b Information available for 316 patients.
c Information available for 217 patients.
d Information available for 295 patients.
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by the IC assay. A higher bacterial load was detected by PCR in
culture-positive specimens in comparison to culture-negative
specimens. The mean combined bacterial load was 8.77 × 108
CFU/mL in culture-positive vs 7.03 × 107 CFU/mL in culture-
negative specimens (P < .0001). Significant differences between
culture-positive and culture-negative specimens were also ob-
served when H. influenzae (P < .0001) and S. pneumoniae
(P < .0001) were considered individually.
Outcomes
Neither culture-positivity nor PCR-positivity was associated
with the outcome of infection (P = .2; odds ratio [OR] = 1.5;
95% confidence interval [CI], .8–2.9; and P = .8; OR = .9; 95%
CI, .4–2.6, respectively). Polymicrobial detection was also not
associated with the outcome of infection (P = .4; OR = 1.3;
95% CI, .7–2.5). The bacterial load of S. pneumoniae was asso-
ciated with the outcome of infection on univariate analysis, with
a higher load present in patients with 30-day mortality and/or
ICU admission (4.33 × 108 CFU/mL vs 1.29 × 108 CFU/mL;
P = .009). However, the CURB-65 score (CURB-65; Confusion
of new onset, blood Urea nitrogen >7 mmol/l , Respiratory rate
≥30 breaths per minute, Blood pressure <90 mmHg systolic or
≤60 mmHg diastolic, age ≥65 years) was also associated with
outcome on univariate analysis (P = .01). When logistic regres-
sion was used to correct for CURB-65 score in patients with
S. pneumoniae infection, bacterial load was no longer signifi-
cantly associated with outcome (P = .09; Supplementary Table 4).
Effect of Antimicrobial Therapy Prior to Microbiological Sampling
Of 316 patients with information available on antimicrobial ad-
ministration prior to sampling, 268 (84.8%) had received anti-
microbials either while in the hospital or in the community
during the 72 hours before an LRT specimen was obtained.
Prior antimicrobial administration was significantly associated
with a patient having a culture-negative LRT specimen
(P < .0001; OR = 9.1; 95% CI, 4.1–22.4). Of the 268 patients
who had received prior antimicrobials, 77.6% (n = 208) had a
bacterial pathogen detected by PCR, but only 32.1% (n = 86)
were culture positive (P < .0001). The mean combined load of
all detected bacteria per patient was significantly higher in pa-
tients who had not received antimicrobials prior to sampling
(5.40 × 109 CFU/mL) compared with those who had received
antimicrobials (2.67 × 108 CFU/mL; P = .0001).
Estimation of Impact on Antimicrobial Prescribing
Records of antimicrobial treatment during hospitalization were
available for 99.1% (n = 320) of patients. Molecular testing had
the potential to lead to de-escalation in number and/or spec-
trum of initial empirical antibiotic agents in 247 (77.2%) pa-
tients, escalation in number and/or spectrum of antibiotic
agents in 19 (5.9%) patients, and no change in 54 (16.9%) pa-
tients (Table 3). The majority of the potential de-escalation
events were related to switching of amoxicillin-clavulanate to
narrower-spectrum agents such as amoxicillin and doxycycline
in cases where S. pneumoniae or H. influenzae were detected by
PCR and to the removal of clarithromycin in cases where atyp-
ical bacteria were not detected by PCR.
DISCUSSION
This study demonstrates that the use of a comprehensive multi-
bacterial, multiviral molecular testing approach approximately
doubles pathogen detection in patients with CAP from 39.3%
to 86.7%, as well as provides valuable information about indi-
vidual bacterial loads. Testing can be carried out within 1 work-
ing day to enable reporting of results in a clinically relevant
time-frame, requires only a single LRT specimen, and is not
Table 2. Pathogen Detection in Patients With Community-Acquired
Pneumonia Using Molecular Methods (n = 323)
Pathogen N (%)
Bacteria
Any bacteria 262 (81.1)
With ≥105 CFU/mL cutoff where quantified 231 (71.5)
Haemophilus influenzae 130 (40.2)
Streptococcus pneumoniae 115 (35.6)
Moraxella catarrhalis 44 (13.6)
Escherichia coli 37 (11.5)
Staphylococcus aureus 33 (10.2)
Klebsiella pneumoniae 13 (4.0)
Pseudomonas aeruginosa 9 (2.8)
Mycoplasma pneumoniae 6 (1.9)
Acinetobacter baumannii 3 (0.9)
Legionella pneumophila 3 (0.9)
Non-pneumophila Legionella spp. 3 (0.9)
Chlamydophila psittaci 2 (0.6)
Chlamydophila pneumoniae 0 (0)
Virus















Respiratory syncytial virus 4 (1.2)
Human metapneumovirus 3 (0.9)
Any pathogena 280 (86.7)
With ≥105 CFU/mL cutoff for bacteria where quantified 263 (81.1)
Abbreviation: CFU, colony-forming unit.
a Codetection of bacteria and virus in 80 patients.
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negatively impacted by antibiotic administration prior to
sampling.
Only limited quantitative molecular bacterial testing has been
carried out in a well-defined CAP setting [21, 25, 28, 29, 31]. As
our study focused on testing sputum by molecular methods, our
high level of pathogen detection for typical bacteria may not be
directly comparable to results from other recent studies in hos-
pitalized adult CAP. By combining several methodologies such
as serology, culture, antigen detection, and PCR on multiple
sample types, etiology was determined in 38%–76% of cases
[4, 7, 21, 31, 36–41]. Atypical bacteria were uncommon in our
cohort (<5% patients), but it was not an epidemic period for
M. pneumoniae [42]. Viruses were detected in approximately
one third of patients, which is in agreement with the 13%–
56% range reported in previous studies; influenza was also de-
tected at comparable levels (<10%) [4, 7, 21, 31, 36, 38, 39, 43].
Although we were not able to test controls, viral detections by
PCR from the upper respiratory tract have been found to be rare
in asymptomatic adults compared with those with CAP in a re-
cent study [43].
One limitation of our study was that it was restricted to CAP
patients who could produce a sputum specimen. Also, we did
not include blood culture or urinary antigen tests. Sputum is
a pragmatic, although imperfect, choice of specimen type for
the microbiological investigation of CAP. Microscopy for spu-
tum quality is not routinely carried out locally; however, only
mucopurulent material was tested, and the cellular content
was quantified by human GAPDH gene PCR to rule out salivary
specimens. However, sputum that is expectorated from the
lower airways will always be at risk of oropharyngeal flora con-
tamination. Despite the limitations, national CAP guidelines [1,
5] recommend sputum investigation for patients admitted to
the hospital with moderate to severe CAP, both to aid microbi-
ological diagnosis in order to guide therapy as well as for sur-
veillance. Alternative lower respiratory specimen types such as
bronchoalveolar lavage fluids may be expected to be less at risk
of contamination, but these require a semi-invasive procedure
that is certainly not routine in nonintubated patients.
A key strength of our study was the availability of quantitative
bacterial load outputs in addition to qualitative detection re-
sults. Quantification of bacterial DNA load may be important
in distinguishing infection from oropharyngeal contamination
in sputum. Most molecular work done to date has focused on
S. pneumoniae, and a cutoff of 104–105 gene copies/mL is typ-
ically described as a significance threshold [20, 21, 29, 44].A cut-
off of 105 CFU/mL is also generally agreed upon for sputum
culture as determined through years of experience. Based on
these data, we applied a significance threshold of ≥105 CFU/
mL for all bacterial loads, and this did not significantly decrease
overall pathogen detection. However, it remains unclear wheth-
er a single molecular cutoff is relevant for all bacterial species
and whether cutoffs for sputum culture are relevant to sputum
PCR. Quantitative molecular tools for many bacterial species
are new [32, 33], and there is a clear need for further exploration
of their role. Determination of thresholds for significant and
nonsignificant detection are key targets for future work.
We found a higher mean bacterial load by PCR in culture-
positive specimens in comparison to culture-negative speci-
mens. However, the culture-negative group was more frequently
antibiotic exposed, and antibiotic exposure was also associated
with lower bacterial loads. As PCR is able to detect dead as well
as viable bacteria, it is not clear for how long bacterial loads
might be detectable after initiation of appropriate antibiotics
Table 3. Estimated Potential Impact of Comprehensive Molecular Testing
on Antimicrobial Prescribing in Patients With Community-Acquired
Pneumonia (n = 320)
Potential Modification Antibiotic Agent N (%)
De-escalation 247 (77.2)




Remove 2 agents 12
CLR +AMX 6
CLR +DOX 6
Reduce spectrum of agent 12
AMC to DOX 8
AMC to AMX 2
Otherb 2
Reduce number and spectrum 110
AMC+CLR to DOX 61
AMC+CLR to AMX 22
AMX+ CLR to AMC 12
AMX+ CLR to DOX 5
CRO+ CLR to DOX 4
AMC+CLR to LEV 2
Otherc 4
Escalation 19 (5.9)
Add 1 agent 2
CIP 1
DOX 1
Increase spectrum of agent 15
CLR to DOX 6
CLR to CIP 3
DOX to AMC 3
Otherd 3
Increase number and spectrum 2
AMX to DOX +CLR 1
CLR to AMX + CIP 1
No change 54 (16.9)
Abbreviations: AMC, amoxicillin-clavulanic acid; AMX, amoxicillin; AZM, azithromycin; CIP,
ciprofloxacin; CLR, clarithromycin; CRO, ceftriaxone; DOX, doxycycline; LEV, levofloxacin.
a DOX (1 patient), CRO (1 patient), AMX (1 patient).
b DOX to CLR (1 patient), DOX to AMX (1 patient).
c AMX+ CLR to CIP (1 patient), AMC +CRO+CLR to CIP (1 patient), AMC+ AZM to AMX (1
patient), AMC+DOX to AMX (1 patient).
d DOX to CIP (1 patient), CLR to AMC (1 patient), AMX to DOX (1 patient).
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in patients with CAP and if monitoring of bacterial load by PCR
would be useful in these patients. With the quantitative molec-
ular tools now available for the relevant bacteria, these issues
can also be further investigated.
A recent review has noted that interventions to reduce excessive
and increase effective antibiotic prescribing in hospitalized patients
can have a positive impact on antimicrobial resistance, hospital-
acquired infections, and clinical outcomes [45]. However, studies
in the pneumonia setting have been small and either focused on
atypical bacteria and viruses [46]or nonquantitative molecular de-
tection of bacteria [30], demonstrating 11% and 67% antibiotic
modification, respectively. The results of comprehensive molecular
testing in our study were not available to the treating physicians
due to the anonymized study protocol. However, we estimated
that de-escalation and/or reduction in the number of agents
might have occurred in three quarters of our CAP patients. This
was based on significantly improved bacterial detection capability,
high rates of broad-spectrum empirical antibiotic usage in our
cohort, and knowledge of local antimicrobial resistance patterns.
Clearly, a large number of additional factors influence antimi-
crobial selection (eg, severity of illness, concurrent infection at
sites other than the lower respiratory tract, drug allergy, antimi-
crobial susceptibility testing, inflammatory markers), and we do
not suggest that sputum PCR testing alone will be sufficient.
However, the lack of positive microbiological identification is a
significant issue, and it is highly likely that enhancing the detec-
tion of pathogens and reporting of bacterial loads would have a
major impact on the clinical decision-making process. Therefore,
our study illustrates the feasibility of providing the physician with
significantly more information on which to base treatment deci-
sions than is currently available and suggests that comprehensive
PCR testing including bacterial load quantitation should be one
of the inputs to future prospective studies in this area.
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